NCT03764293 2024-02-06
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
Clinical Trials
7 trialsNCT05854849 2023-05-11
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Sun Yat-sen University
Phase 3 Recruiting
NCT03396211 2023-04-07
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
Phase 1 Completed
NCT05095636 2021-10-27
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Fudan University
Phase 2 Unknown
NCT03913182 2020-02-05
Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
Shanghai Chest Hospital
Phase 2 Unknown
NCT04180007 2019-11-27
APT-01
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT02711007 2018-04-23
Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Peking University People's Hospital
Phase 2/3 Completed